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BEHAVIORAL NEUROSCIENCE
Volkow et al., 1988; Terwilliger et al., 1991; Stimmel and Kreek, 
2000; Kreek, 2001; Kosten and George, 2002). Opiates are said 
to deregulate the noradrenergic system and second messenger 
pathways such as adenylyl cyclase (AC) and cyclic AMP (cAMP; 
Nestler, 1993; Gintzler and Chakrabarti, 2006). The central 
noradrenergic system, especially the locus ceruleus, is rendered 
hypoactive as a result of dependence, and becomes hyperactive 
during opiate withdrawal (Aghajanian, 1978; Akaoka and Aston-
Jones, 1991). In addition chronic reduction of noradrenaline 
release up-regulates both beta-1 and alpha-1 receptors and causes 
functional supersensitivity to noradrenaline (Kuriyama et al., 
1981a,b; Mogilnicka, 1986). Stimulation of the beta-adrenergic 
receptor also leads to activation of AC and cAMP which have a 
direct impact on gene transcription and regulation of memory 
processes (Tronson and Taylor, 2007). Beta-receptors promote 
consolidation, reconsolidation, and retrieval while alpha receptors 
modulate this effect (Kuriyama et al., 1981b; Ferry et al., 1999; 
Sirvio and MacDonald, 1999; Kobayashi and Yasoshima, 2001; 
Sara, 2009; Gibbs et al., 2010) in various ways. In animals that 
have never been drug dependent, blocking this pathway with the 
beta-adrenergic antagonist propranolol disrupts  reconsolidation 
IntroductIon
The treatment of drug addiction is characterized by a high inci-
dence of relapse among recovered addicts, even after many years 
of abstinence (See, 2002). One reason for this is persistent drug 
craving which develops during the course of addiction as a result 
of associations between the rewarding effects of the drug and 
environmental cues (Eikelboom and Stewart, 1982; Childress 
et al., 1993; Frenois et al., 2005). Recently there has been interest 
in methods to attenuate cue-elicited craving and relapse (Tronson 
and Taylor, 2007). In animal tests, treatments such as proprano-
lol, ketamine, or MK-801 disrupt memory reconsolidation for 
contextual cues previously associated with a rewarding drug such 
as morphine, amphetamine, or cocaine (Bernardi et al., 2006; 
Robinson and Franklin, 2007b; Sadler et al., 2007; Brown et al., 
2008; Fricks-Gleason and Marshall, 2008; Zhai et al., 2008). These 
results suggest that reconsolidation-blocking procedures might 
have promise as a form of therapeutic treatment for prevent-
ing relapse in recovered addicts. However, one key element of 
addiction has not been explored in this context. Addiction typi-
cally occurs after prolonged drug use that leads to neural changes 
associated with dependence and tolerance (Lukacher et al., 1987; 
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doi: 10.3389/fnbeh.2011.00042for a place preference conditioned by morphine (Robinson and 
Franklin, 2007b) or cocaine (Bernardi et al., 2006), but the impact 
of chronic morphine on the effect of propranolol in reconsolida-
tion is not known. Since propranolol’s memory blocking effects 
presumably depend on its interference with noradrenergic mem-
ory mechanisms, the question arises as to whether the effects of 
chronic exposure to morphine on the noradrenergic system, alter 
the effect of propranolol as a reconsolidation-blocking agent.
Chronic morphine exposure alters the expression of a variety of 
receptors including GABAa receptors (Ammon-Treiber and Hollt, 
2005). Benzodiazepines such as midazolam, which act as a GABAa 
agonist, suppress signs of morphine withdrawal in both rats and 
mice, and it has been suggested they can decrease morphine toler-
ance and dependence in the rat by interacting with the opioidergic 
system (Rattan and Tejwani, 1997; Cao et al., 2002). Like proprano-
lol, midazolam disrupts memory reconsolidation of conditioned 
fear (Bustos et al., 2006, 2009; Zhang and Cranney, 2008), and 
of a morphine conditioned place preference (CPP; Robinson and 
Franklin, 2010), but it has been tested only in non-dependent rats. 
Currently the impact of GABAa receptor modifications induced by 
chronic morphine on the effects of midazolam in reconsolidation 
is not known.
We have therefore examined the effect of propranolol and 
midazolam on the reconsolidation of a morphine-CPP in rats 
with (1) no prior chronic morphine experience, (2) rats main-
tained on high doses of chronic morphine during both condi-
tioning and reactivation, and (3) in animals where reactivation 
occurred after 10 days of withdrawal from previous chronic mor-
phine experience. Since chronic morphine experience occurring 
at the time of morphine place conditioning might strengthen 
the CPP and render it harder to disrupt, we hypothesized that 
repeated reconsolidation-blocking treatments may potentiate the 
amnestic effects (Sadler et al., 2007; Fricks-Gleason and Marshall, 
2008; Robinson and Franklin, 2010). Therefore animals with a 
history of chronic morphine treatment were subjected to eight 
reconsolidation-blocking sessions. Propranolol was used in a 
dose of 10 mg/kg because this dose has been shown to block 
the increase in excitability of hippocampal neurons induced by 
noradrenaline (Kitchigina et al., 1997) and to disrupt memory 
reconsolidation in appetitive and fear paradigms (Przybyslawski 
et al., 1999; Robinson and Franklin, 2007b, 2010; Lee and Everitt, 
2008). Midazolam was used in a dose of 1 mg/kg because this 
dose blocks reconsolidation (Bustos et al., 2006; Robinson and 
Franklin, 2010) but does not produce strong sedation in young 
rats (Bessa et al., 2005).
MaterIals and Methods
anIMals
Subjects were male Long Evans rats (125–150 g) from Charles River, 
St Constant, QC, Canada. They were weighed and handled daily 
beginning 3–5 days prior to the start of place conditioning. Rats 
were individually housed in a colony room, maintained on a 12-h 
light–dark cycle (lights on at 7 am) with a constant temperature of 
approximately 21°C, and had food and water available ad libitum. 
This research was reviewed by the Animal Ethics Committee of 
McGill University and carried out in accordance with the guidelines 
of the Canadian Council on Animal Care.
apparatus
The CPP apparatus consisted of three compartments, as previously 
described (Robinson and Franklin, 2007b). Compartments A and 
B were identical in size (36 cm × 34 cm × 26 cm), but differed 
in floor and ceiling color (black vs white), the orientation of the 
stripes on the wall (vertical vs horizontal), and by the diameter 
of the wire mesh flooring (1.2 vs 0.6 cm). They were located side 
by side and had shaded plexiglass front walls. Compartment C 
(20 cm × 14 cm × 28 cm) was attached to the rear of compartments 
A and B and connected them via guillotine doors in the rear wall 
of compartments A and B. When the doors were lowered, the rat 
was confined to one of the larger compartments. When the doors 
were removed, the rat could move freely between compartments A 
and B via compartment C. Position sensors in each compartment 
were connected to a computer which calculated the location of the 
animal at all times.
place condItIonIng procedure
On the first day of training animals were introduced via box C and 
allowed to explore freely all three boxes for 30 min. Time spent in 
each compartment was recorded, and was used to verify that the rats 
did not exhibit any spontaneous preference for a given compartment.
On each conditioning day the rat was brought to the test room, 
injected (s.c.) with the drug (or vehicle), and immediately confined 
to compartment A or B for 30 min. On alternate days, the rat was 
injected with the vehicle (or drug), and confined for 30 min to the 
other compartment. The order of injection (drug or vehicle) and 
the compartment paired with the drug (A or B) was counterbal-
anced within each group. On test days each rat was introduced via 
the alley box (box C) and allowed to move freely in all three boxes 
for 30 min. Time spent in each compartment was recorded.
chronIc MorphIne treatMent: InductIon and MaIntenance
Rats received single daily injections of morphine (s.c.) around 6 pm 
each day, starting 5 days before CPP training. They received 10 mg/
kg on day 1 and the dose was increased by 5 mg/kg each day up to 
30 mg/kg the day before training began. Rats were subsequently 
maintained on daily injections of 30 mg/kg until withdrawal was 
induced by cessation of the treatment. Previous studies have shown 
that either a single injection of morphine (30 mg/kg, s.c.) or daily 
injections (10 mg/kg, s.c.) over a period of 14 days, produces behav-
ioral sensitization and neuroadaptations that last up to 3 weeks 
(Vanderschuren et al., 1997, 2001), and doses as low as 10 mg/kg 
for 5 days induce dependence as indicated by naloxone-precipitated 
withdrawal signs (Frumkin, 1974; Mucha et al., 1979).
After their last dose of morphine rats were withdrawn for 
10 days. According to several studies, most of the symptoms of 
withdrawal have disappeared after 10 days of abstinence (Cox and 
Valenstein, 1969; Khavari et al., 1975; Stinus et al., 1998; Gekht 
et al., 2003).
experIMent 1: the effect of propranolol and MIdazolaM on 
reconsolIdatIon In MorphIne-naIve rats
Morphine-naïve rats were pre-exposed to the apparatus on the first 
day and then conditioned with four drug (morphine 5 mg/kg, s.c.) 
pairings and four vehicle pairings over eight consecutive days. The 
day following conditioning, rats received a 30-min test which also 
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duration of, conditioning and reactivation sessions, in the same 
manner as in Experiment 2a. However in this case animals received 
injections of the peripheral beta-blocker nadolol (10 mg/kg, s.c.) 
after each reactivation session.
experIMent 3: reconsolIdatIon In anIMals MaIntaIned on 
chronIc MorphIne treatMent durIng condItIonIng, but not 
reactIvatIon.
The aim of this experiment was to assess whether the effects of 
chronic morphine treatment on reconsolidation were long lasting, 
and would persist if reactivation occurred following discontinu-
ation of chronic morphine treatment. This experiment followed 
the same protocol as Experiment 2 with regards to the induction 
and maintenance of chronic morphine treatment (30 mg/kg/day, 
s.c.) and conditioning. However, rats received their last chronic 
morphine injection on the final day of conditioning. Morphine 
maintenance was discontinued for 10 days before the reactivation 
protocol began. As in Experiment 2, animals were reactivated once a 
day for eight consecutive days, and injected with either propranolol 
(s.c.), midazolam (i.p.), or vehicle immediately after each session.
experIMent 4: the effect of post-trIal propranolol InjectIons 
In MorphIne MaIntaIned and MorphIne-naIve anIMals
The aim of this experiment was twofold. First it examined whether 
a single post-session propranolol injection could induce a change in 
preference for the compartment with which it was explicitly paired. 
In other words, can a single injection of propranolol that is pre-
dicted by exposure to an environment impart motivational proper-
ties to that environment, which could interact with   motivational 
acted as a reactivation session. Immediately after reactivation rats 
received an injection of propranolol (10 mg/kg, s.c.), midazolam 
(1 mg/kg, i.p.), or vehicle. Animals were tested 2 and 7 days after reac-
tivation to see if the memory for the CPP persisted. The design of this 
experiment and Experiment 2a and b are summarized in Figure 1.
experIMent 2a: the effect of propranolol and MIdazolaM on 
reconsolIdatIon In anIMals MaIntaIned on chronIc MorphIne 
treatMent durIng condItIonIng and reactIvatIon
The second experiment differs from the first in that rats were sub-
mitted to a chronic morphine regimen (30 mg/kg/day, s.c.) prior to 
training, and maintained under this regimen throughout condition-
ing and reactivation. Conditioning was the same as Experiment 1. In 
order to reduce the possibility of overdose, animals were conditioned 
around midday each day with morphine (5 mg/kg, s.c.) or saline, and 
received their chronic morphine maintenance dose around 6 pm.
The reactivation sessions began 48 h after the last condi-
tioning session and were repeated eight times, at 24 h intervals. 
Each reactivation session doubled as a test of the previous treat-
ment. Immediately after each reactivation session, animals were 
injected with either propranolol (s.c.), midazolam (i.p.), or vehicle. 
Following the eighth reactivation session, morphine maintenance 
was discontinued and animals were re-tested drug free after 10 days.
experIMent 2b: the effect of a perIpheral beta-blocker on 
reconsolIdatIon In anIMals MaIntaIned on chronIc MorphIne 
treatMent durIng condItIonIng and reactIvatIon
This experiment assessed the effect of peripheral beta-blockade 
on reconsolidation in chronically morphine treated animals. A 
single group of animals was induced and maintained on a chronic 
Figure 1 | Schematic diagram of the sequence of events and procedures 
in experiments 1, 2a, 2b, and 3. Amnestic drugs are propranolol, midazolam, 
nadolol, or saline, depending on the experiment. Dark and light shaded areas 
below an experiment represent the escalation and maintenance of chronic 
morphine treatment and the transition to forced abstinence. Vertical dashed 
lines divide the different phases of each experiment.
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tailed (alpha = 0.05). In Experiment 4 the effect of propranolol was 
unknown so two-tailed Tests were used. Note that this strategy is 
conservative because incorrectly accepting the null hypothesis for 
the CPP would increase the probability of reporting a reconsolida-
tion block where none was present.
We also determined whether there were significant shifts in pref-
erence within treatment groups from the initial preference on the 
first reactivation to each subsequent reactivation (Experiments 1, 
2a, and 3). The ANOVA (Statistica) was with one repeated meas-
ure, comparing the preference score (time spent in drug compart-
ment − time in saline compartment) on the initial reactivation day 
against the preference score on each subsequent test/reactivation 
day (two-tailed).
For Experiment 2b, t-tests were used to confirm a preference 
for the morphine context (time spent in morphine vs saline-paired 
compartment), and to compare the preference score (time spent in 
morphine − saline-paired compartment) on the initial reactivation 
to the preference score on each subsequent reactivation.
An ANOVA comparing the time spent in the left vs the right 
compartment for each group was run on the pre-exposure session 
for each experiment to confirm the apparatus was unbiased. The 
pre-exposure scores were not used in the calculation of the size 
of the CPP.
To assess the effect of propranolol as a reconsolidation treatment 
on a morphine-induced CPP across varying levels of chronic mor-
phine experience (Experiments 1, 2a, and 3), the preference score on 
the initial reactivation day for the three propranolol-treated groups 
was compared to the preference expressed on the following test day.
results
experIMent 1: the effect of propranolol and MIdazolaM on 
reconsolIdatIon In MorphIne-naIve rats
During pre-exposure to the apparatus none of the groups displayed 
a significant preference for either compartment [F(2,27) = 0.194, 
NS], confirming the apparatus was unbiased.
After four cycles of conditioning, all three groups displayed 
a significant preference for the drug-paired compartment 
[Reactivation: Propranolol: F(1,27) = 38.314, p < 0.001; Midazolam: 
F(1,27) = 30.187, p < 0.001; Saline: F(1,27) = 20.615, p < 0.001]. 
There was no difference in preference between these three groups 
[F(2,27) = 0.499, NS; Figure 2].
Two days later, animals were tested (Test 1) to assess the effect of 
the previous amnestic treatment on the morphine place preference. 
As can be seen in Figure 2, the group administered saline follow-
ing initial reactivation still displayed a significant place preference 
[Saline: F(1,27) = 6.395, p < 0.001]. However, the groups injected 
post-reactivation with propranolol or midazolam no longer dis-
played a preference for the drug-paired compartment [Propranolol: 
F(1,27) = 1.374, NS; Midazolam: F(1,27) = 2.103, NS]. For the 
propranolol-treated group the decline in preference from the reac-
tivation session was significant [F(1,27) = 5.013, p < 0.025].
When animals were re-tested 7 days after initial the reactivation, 
the saline group again displayed a preference for the drug-paired com-
partment [Saline: F(1,27) = 5.919, p < 0.01], whereas the propranolol 
and midazolam treated groups did not [Propranolol: F(1,27) = 1.435, 
NS; Midazolam: F(1,27) = 1.041, NS]. In addition, for the groups 
properties imparted by CPP conditioning. Second, it examined 
whether repeated pairings, in this case four, of post-session injec-
tions of propranolol with a compartment could impart motiva-
tional properties to that environment. Prior to any behavioral 
procedures one group of rats was maintained on chronic morphine 
treatment as previously described, while another group received 
repeated saline injections. Following an initial pre-exposure ses-
sion, animals were confined to one compartment for 30 min and 
received a propranolol (10 mg/kg, s.c.) injection upon exiting the 
compartment designated as CS+. Animals received a saline injec-
tion on the alternate day following a 30-min exposure to the other 
compartment. Twenty-four hours later, all animals were allowed to 
run freely between compartments and their time in each compart-
ment was recorded, to assess whether a place preference or aver-
sion had developed. The 2-day cycle of conditioning was repeated 
three more times over the next 6 days for a cumulated total of four 
propranolol and four saline pairings. The next day both groups of 
rats were tested with a free choice of compartment.
drugs and InjectIons
For conditioning, morphine sulfate (Sabex, QC, Canada) was 
diluted to 5 mg/ml in 0.9% sodium chloride (saline), and given 
(s.c.) at a dose of 1 ml/kg. Saline was used for control injections 
in the same volume. For induction and maintenance of chronic 
morphine treatment, morphine sulfate was diluted to 10 and 30 mg/
ml in 0.9% sodium chloride (saline).
Propranolol hydrochloride and nadolol (Sigma-Aldrich, USA, 
Ltd.) were dissolved in 0.9% sodium chloride to a concentration of 
10 mg/ml and given subcutaneously. Midazolam (Sandoz, Canada, 
Inc.) was provided in vials of 5 mg/5 ml and injected (i.p.) at a 
dose of 1 mg/kg. We have previously found that there is no effect 
of the route of injection of saline (Robinson and Franklin, 2010) so 
controls received an equivalent volumes of saline subcutaneously.
statIstIcal analysIs
Data collected during pre-exposure and test/reactivation sessions 
consisted of time spent in seconds in each of the three chambers 
in the apparatus. Animals which did not display a preference (drug 
time − saline time > 0) for the drug-paired compartment on the first 
reactivation were excluded from analysis [Experiment 1 (1 out of 
31); Experiment 2a (0 out of 38), 2b (0 out of 13); Experiment 3 (4 
out of 40); Experiment 4 (Propranolol conditioning – no animals 
excluded)].
The experimental hypotheses were that morphine produces a 
CPP, amnestics attenuate the memory for the CPP, and that this 
effect is stable over time. These hypotheses are most powerfully 
tested by within group comparisons. The hypotheses specify which 
group differences are meaningful and the direction of effects. We 
therefore used ANOVA with planned contrasts to maximize power. 
We first examined whether each group showed a significant prefer-
ence for the drug-paired over the vehicle-paired compartment on 
each trial. The ANOVA (Statistica) was with one repeated meas-
ure (the time each animal spent in either compartment). In this 
design only a subset of the possible between-cell comparisons is 
meaningful so we used a priori contrasts to increase power and 
reduce the risk of Type II errors. Since morphine is known to 
produce a CPP it was predicted that all groups would prefer the 
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compartment previously associated with morphine [Reactivation 
1 to Reactivation 2–4: Fs (1,35) > 5.510, p < 0.025].
Reactivation 8 (Test 7) marked the end of reconsolidation treat-
ments and the last day of chronic morphine maintenance. Following 
10 days of forced abstinence all three groups displayed a significant 
place preference [Test 8: Propranolol: F(1,35) = 4.406, p < 0.025; 
Midazolam: F(1,35) = 3.795, p < 0.05; Saline: F(1,35) = 3.165, 
p < 0.05; Figure 4]. However, for both the saline and midazolam 
treated animals the preference was decreased from their initial 
preference [Reactivation 1 to Test 8: Midazolam: F(1,35) = 5.809, 
p < 0.025; Saline: F(1,35) = 5.337, p < 0.05].
experIMent 2b: the effect of a perIpheral beta-blocker on 
reconsolIdatIon for anIMals MaIntaIned on chronIc 
MorphIne treatMent durIng condItIonIng and reactIvatIon
As can be seen in Figure 4, these animals displayed a significant 
preference for the drug-paired compartment on the initial reac-
tivation [F(1,12) = 48.03, p < 0.001]. The preference remained 
treated with propranolol and midazolam the CPP was reduced rela-
tive to the initial reactivation [Reactivation to Test 2: Propranolol: 
F(1,27) = 5.265, p < 0.05; Midazolam: F(1,27) = 4.283, p < 0.05].
experIMent 2a: the effect of propranolol and MIdazolaM on 
reconsolIdatIon In anIMals MaIntaIned on chronIc MorphIne 
treatMent durIng condItIonIng and reactIvatIon
There was no preference for either compartment prior to condi-
tioning [F(2,35) = 1.888, NS].
Upon initial reactivation, following four morphine/saline condi-
tioning pairings, all three groups displayed a significant preference 
for the drug-paired compartment [Reactivation 1: Propranolol: 
F(1,35) = 44.585, p < 0.001; Midazolam: F(1,35) = 62.273, p < 0.001; 
Saline: F(1,35) = 55.057, p < 0.001], and there was no significant 
difference in preference between the three groups [ANOVA, 
F(2,35) = 0.921, NS; Figure 3]. Immediately after this first reacti-
vation session, animals were injected with propranolol, midazolam, 
or saline, and this procedure was repeated every 24 h for the next 
7 days, for a total of eight reactivation sessions. During the course of 
these reactivation/test sessions (Figure 3), the animals treated with 
saline displayed a consistent preference for the drug-paired com-
partment [Reactivation 1–8: Fs (1,35) > 6.293, p < 0.01]. Similarly, 
the animals given midazolam after each reactivation session contin-
ued to show a CPP [Reactivation 1–8: Fs (1,35) > 5.889, p < 0.01], 
as did the group receiving propranolol following each reactivation 
[Reactivation 1–8: Fs (1,35) > 3.696, p < 0.05]. For the midazolam 
and saline treated groups, the size of the preference did not change. 
Figure 2 | effect of Propranolol (10 mg/kg; N = 10), Midazolam (1 mg/kg; 
N = 9), or Saline (N = 11) given post-reactivation, on the expression of a 
morphine-induced place preference (experiment 1). Data are the mean 
time spent in the morphine-paired compartment minus time in the 
vehicle-paired compartment on reactivation, or tests 2 or 7 days post-
reactivation. Error bars = SEM. * = p < 0.05 for morphine vs vehicle-paired; 
# = p < 0.05 for reactivation vs test.
Figure 3 | effect of Propranolol (10 mg/kg; N = 13), Midazolam (1 mg/kg; 
N = 12), or Saline (N = 13) given post-reactivation on the expression of a 
morphine-induced place preference, in animals conditioned and 
reactivated under chronic morphine treatment (experiment 2a). Data are 
the mean time spent in the morphine-paired compartment minus time in the 
vehicle-paired compartment on reactivations 1–8, or when tested after 10 days 
of withdrawal (Test 9). Error bars = SEM. * = p < 0.05 for morphine vs 
vehicle-paired; # = p < 0.05 for difference from reactivation 1.
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preference for the drug-paired compartment on all eight reacti-
vation sessions [Reactivation 1–8: Propranolol: Fs (1,33) > 6.124, 
p  < 0.015]. Furthermore, the size of the drug-side preference 
increased between the first and fifth reactivation, after four post-
reactivation propranolol treatments [Reactivation 1 to Reactivation 
5: Propranolol: F(1,33) = 10.225, p < 0.001]. The group treated 
with midazolam following each reactivation session displayed a 
significant preference for the drug-paired compartment on all but 
the sixth reactivation session [Reactivation 6: F(1,33) = 2.715, NS; 
Reactivation 1–8: Fs (1,33) > 2.950, p < 0.05].
significant throughout the reactivation sessions [Fs(1,12) > 4.12, 
p < 0.05]. Rats given nadolol post-reactivation did not shift their 
preference from their initial reactivation on any of the seven 
following reactivation sessions [F(1,12) < 0.77, NS]. Following 
10 days of withdrawal, the nadolol-treated animals still dis-
played a significant preference for the drug-paired compartment 
[F(1,12) = 6.55, p < 0.01] but the CPP was smaller than on the 
initial test [F(1,12) = 16.42, p < 0.05].
experIMent 3: reconsolIdatIon In anIMals MaIntaIned on 
chronIc MorphIne treatMent durIng condItIonIng, but not 
reactIvatIon
The pre-exposure revealed no initial bias for either compartment 
[F(2,33) = 0.727, NS].
Following four cycles of conditioning under chronic morphine 
treatment, morphine maintenance injections were stopped and 
animals were allowed to recover over the course of 10 days before 
beginning the reactivation phase. On the initial reactivation, all 
three groups displayed a significant preference for the drug-paired 
compartment [Reactivation 1: Propranolol: F(1,33) = 38.792, 
p  < 0.001; Midazolam: F(1,33) = 26.561, p  < 0.001; Saline: 
F(1,33) = 37.189, p < 0.001], and there was no significant differ-
ence in preference between the groups [ANOVA, F(2,33) = 0.171, 
NS; Figure 5]. Twenty-four hours after post-reactivation treatment 
with saline, the controls retained a significant place preference 
which persisted for six reactivation sessions [Reactivation 1–6: 
Saline: Fs (1,33) > 5.135, p < 0.05] but faded on reactivation 7 
and 8 [Saline: Fs (1,33) < 0.991, NS]. For the last two reactivation 
sessions the preference decreased significantly from the preference 
on reactivation 1 [Reactivation 1 to Reactivation 7/8: Saline: Fs 
(1,33) > 4.949, p < 0.05].
Figure 4 | effect of Nadolol (10 mg/kg; N = 13) given post-reactivation 
on the expression of a morphine-induced place preference, in animals 
conditioned and reactivated under chronic morphine treatment 
(experiment 2b). Data are the mean time spent in the morphine-paired 
compartment minus time in the vehicle-paired compartment on reactivations 
1–8, or when tested after 10 days of withdrawal (Test 9). Error bars = SEM. 
* = p < 0.05 for morphine vs vehicle-paired; # = p < 0.05 for difference from 
reactivation 1.
Figure 5 | effect of Propranolol (10 mg/kg; N = 12), Midazolam (1 mg/kg; 
N = 11), or Saline (N = 13) given post-reactivation on the expression of a 
morphine-induced place preference, in animals conditioned under 
chronic morphine treatment, but reactivated following 10 days of 
withdrawal (experiment 3). Data are the mean time spent in the morphine-
paired compartment minus time in the vehicle-paired compartment on 
reactivations 1–8. Error bars = SEM. * = p < 0.05 for morphine vs vehicle-
paired; # = p < 0.05 for difference from reactivation 1. 
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Across all three experiments, rats receiving 30 mg/kg morphine daily 
gained weight more slowly than rats that only received condition-
ing drug injections. After 2 weeks of chronic morphine treatment, 
there was a significant difference in percentage weight gain across 
the three experiments on day 15 [F(2,101) = 141.239, p < 0.05]. The 
morphine-maintained animals in Experiment 2 had an average daily 
weight gain of 4.92 g. Similarly the animals in Experiment 3 gained 
at an average daily rate of 5.10 g/day. In the same amount of time, 
the control animals from Experiment 1 increased at a rate of 7.78 g/
day. After 2 weeks of chronic morphine experience the animals in 
Experiment 3 were taken off daily morphine injections. During the 
following 9 days they increased in body weight at a rate of 9.93 g/
day. While animals from Experiment 2 continued their morphine 
regimen for those 9 days, displaying a daily rate of weight increase 
of 6.30 g/day. The percentage increase in weight on day 24 was 
significantly different between groups [F(1,60) = 37.920, p < 0.05].
When the preference for the drug-paired compartment on the 
initial test was compared across experiments, it was found that 
chronic morphine treatment significantly increased the prefer-
ence for the drug-paired compartment only if the animals were 
being chronically treated at the time of the test [F(2,101) = 4.814, 
p > 0.05]. A CPP in animals conditioned while maintained on mor-
phine but reactivated following withdrawal was no different than 
one in animals trained and tested naïve [F(1,101) = 0.087, NS].
dIscussIon
Propranolol and midazolam administered after reactivation, 
disrupted a morphine-conditioned CPP in rats that were not 
chronically treated with morphine. These results replicate previ-
ous demonstrations in animals not maintained on morphine that 
the IMpact of chronIc MorphIne experIence on propranolol’s 
effect on reconsolIdatIon
Figure 6 shows the impact of chronic morphine experience on the 
effect of propranolol as a reconsolidation-blocking treatment given 
after the initial reactivation. As can be seen, there was an interac-
tion between chronic morphine treatment and the reactivation 
trial [F(2,32) = 8.304, p < 0.01]. When the trials were considered 
separately, there were no differences between the groups on trial 
1 before propranolol treatment [F(2,32) = 0.275; NS]. However, 
after reconsolidation (reactivation 2) an effect of chronic morphine 
treatment was apparent [F(2,32) = 8.225, p < 0.01]. Chronically 
treated (Experiment 2a) subjects had a significantly larger pref-
erence than naïve subjects (Experiment 1; Tukey HSD, p < 0.05). 
Animals with a history of chronic morphine treatment but that 
were reactivated following withdrawal (Experiment 3) had a mar-
ginally larger CPP than naïve subjects (Tukey HSD, p = 0.051) but 
did not differ from chronically treated subjects (Experiment 2a).
experIMent 4: the effect of post-trIal propranolol InjectIons 
In MorphIne MaIntaIned and MorphIne-naIve anIMals
The pre-exposure revealed no initial bias for either compartment 
[F(1,19) = 0.164, NS].
Following a single pairing with propranolol neither chronically 
treated or naive animals showed a preference for one compartment, 
as can be seen in Figure 7 [Test 1: Chronic morphine: F(1,19) = 0.419, 
NS; Naive: F(1,19) = 0.146, NS]. However, when animals were tested 
after four conditioning cycles, both groups displayed a significant place 
aversion for the propranolol-paired compartment [Test 2: Chronic 
morphine: F(1,19) = 18.230, p < 0.001; Naive: F(1,19) = 4.737, 
p < 0.05]. There was no significant difference in the size of the aver-
sion between groups on Test 2 [ANOVA: F(1,19) = 2.523, NS].
Figure 6 | The figure compares the preference for the morphine-paired 
context of the propranolol-treated groups on the initial reactivation and 
the subsequent reconsolidation test, for different degrees of experience 
with morphine (experiment 1: Naive; experiment 2a: Chronic morphine; 
experiment 3: Withdrawn). Data is the mean time spent in the morphine-
paired compartment minus time in the vehicle-paired compartment on the 
initial reactivation and the following test day. Error bars = SEM. 
Figure 7 | Place conditioning with post-trial propranolol as the 
reinforcer, in Chronic morphine (N = 10), and Naive (N = 11) animals 
(experiment 4). Data are the mean time spent in the propranolol-paired 
compartment minus time in the vehicle-paired compartment on Tests 1 and 2. 
Error bars = SEM. * = p < 0.05 for propranolol- vs vehicle-paired. 
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CPP is increased on reactivation 5 in animals maintained on mor-
phine after four repeated post-reactivation propranolol injections 
(Experiment 3) cannot be explained by a preference-inducing effect 
of propranolol. In addition, although these results do suggest that 
repeated propranolol injections produce what appear to be signs of 
aversion, it should be noted that animals with a history of chronic 
morphine treatment retained a morphine CPP longer than their 
saline treated counterparts, despite seven propranolol injections.
Comparison of the body-weight changes for the animals 
maintained on morphine showed the pattern typical of opioid 
  dependence – a marked decrease in the rate of weight gain in 
chronically treated animals followed by a slow recovery after several 
days of abstinence. Chronic morphine experience also increased the 
size of the initial preference for the drug-paired side if the animals 
were maintained on morphine at the time of the test. Animals con-
ditioned while maintained on morphine but reactivated following 
withdrawal were no different than animals trained and tested naïve. 
In contrast Harris and Aston-Jones (2003), found that chronically 
morphine pretreated abstinent rats showed a stronger preference 
for the morphine-paired environment than placebo pretreated rats. 
However their procedure differed from ours in several ways. They 
used morphine pellet implants to induce dependence, they ran two 
training sessions per day and they gave three drug-compartment 
pairings rather than four. It is possible that our subjects were more 
trained and have reached asymptote for the CPP, thus obscuring 
increased sensitivity in dependent animals.
The fact that animals trained while maintained on morphine 
became resistant to the reconsolidation-blocking effect of both 
propranolol and midazolam can possibly be explained by facili-
tation of conditioning by chronic morphine treatment. We have 
previously shown that a strongly conditioned CPP is resistant to 
reconsolidation block (Robinson and Franklin, 2010), and it has 
been shown that sensitization to morphine speeds conditioning 
(Mucha et al., 1982; Lu et al., 2002). We have observed that a single 
morphine-context pairing is sufficient to produce a reliable CPP in 
morphine-sensitized animals (Robinson, 2009) whereas in naïve 
animals conditioning requires several trials (Robinson and Franklin, 
2007a). Chronic morphine exposure could be considered as extreme 
sensitization, and it would be expected to facilitate conditioning 
so that the conventional four morphine pairings would produce 
strong conditioning resistant to reconsolidation block. In addition, 
it is possible that down regulation of GABAa receptors as a result of 
chronic exposure to morphine (Ammon-Treiber and Hollt, 2005) 
contributes to the loss of the amnestic effect of midazolam. However 
neither of these hypotheses can explain the increase in the size of the 
CPP produced by post-reactivation propranolol in animals trained 
while maintained on morphine. The effect is centrally mediated 
since a peripheral beta-blocker did not reproduce the effect. It can-
not be due to direct interaction with morphine, because propranolol 
was never given in conjunction with morphine, and the effect was 
still present in animals that had recovered from chronic morphine. 
Since neither propranolol nor morphine are present at the time the 
CPP is expressed the effect must be mediated by memory. It is pos-
sible that the expression of the preference in the reactivation trial 
could accidentally make the morphine-associated chamber become 
a predictor of propranolol administration but even if this could 
propranolol disrupts reconsolidation for a CPP induced by mor-
phine (Robinson and Franklin, 2007b, 2010). We have previously 
demonstrated (Robinson and Franklin, 2007b) that such disruption 
of the CPP by propranolol is reactivation dependent, which is char-
acteristic of reconsolidation block. Prior research using midazolam 
as a reconsolidation-blocking agent has examined only fear condi-
tioning (Bustos et al., 2006, 2009; Zhang and Cranney, 2008), but 
we have now found that midazolam also blocks reconsolidation 
of an appetitive CPP, and that the block persists over several tests.
When animals were conditioned and reactivated while receiving 
daily maintenance doses of morphine, the results were strikingly 
different from those with naive animals. Neither midazolam nor 
propranolol interfered with reconsolidation, even after multiple post-
reactivation treatments. Instead, propranolol produced a significant 
increase in the preference for the compartment previously paired with 
morphine. This effect was not the result of peripheral beta-adrenergic 
blockade or the reactivation procedure since injections of nadolol, 
which does not readily cross the blood–brain barrier, did not increase 
the CPP. It is possible that higher doses might have overcome the 
resistance to reconsolidation but the dose of 10 mg/kg propranolol 
is the dose most commonly used in the literature on reconsolidation, 
and is 20 times greater than the dose required to block the memory 
enhancing effect of systemic epinephrine (Sternberg et al., 1985). 
Thus our results show that chronic exposure to morphine markedly 
alters the effect of a reconsolidation-blocking treatment, as can be 
seen when the effect of propranolol on reconsolidation is compared 
across groups with differing histories of morphine exposure.
Failure of both midazolam and propranolol to block recon-
solidation in chronically treated animals cannot be attributed to 
concomitant morphine treatment at the time of reactivation. When 
animals were reactivated following 10 days of withdrawal, neither 
propranolol or midazolam attenuated the preference for the drug-
paired compartment. Again, propranolol seemed to enhance the 
preference for the drug-paired compartment, though the effect 
occurred only after several treatments. In the controls, the CPP 
appeared to extinguish after five reactivations but propranolol-
treated animals continued to prefer the drug-paired compartment 
longer than their saline treated counterparts.
There is very little chance that a post-reactivation treatment 
would be consistently and exclusively associated with either con-
text, nevertheless we explored (Experiment 4) whether post-trial 
propranolol could act as a reinforcer in rats. Explicitly pairing an 
exposure to one compartment with a subsequent injection of pro-
pranolol, and to the alternate compartment with an injection of 
saline, did not produce a preference or aversion for the compart-
ment associated with propranolol treatment in either chronically 
treated or morphine-naive animals. This shows that even with a per-
fect association between a compartment and propranolol the moti-
vational significance of the CPP context is not altered by a single 
experience of propranolol. Thus, the development of a conditioned 
aversion to the “morphine-paired” side cannot explain the loss of 
the CPP in morphine-naïve subjects (Experiment 1). Similarly, the 
significant increase in preference in chronically treated animals after 
post-reactivation propranolol cannot be explained by the develop-
ment of an additional propranolol-conditioned preference for the 
“morphine-paired” side (Experiment 2a). After four conditioning 
trials with propranolol, however, an aversion to the compartment 
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